Drawing for IXACTILE

USPTO serial 79363506

IXACTILE

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
NGUYEN, NICOLE ASHLEY
Law office
TMO LAW OFFICE 114 - MANAGING ATTORNEY

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with IXACTILE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Chemicals for use in science, scientific research and for laboratory use; analytical and diagnostic reagents for in vitro useACTIVE—
005Medicines; pharmaceutical and veterinary preparations; chemical, analytical and diagnostic reagents for in vivo use, for medical purposes; chemicals for use in medical research, and medical or veterinary diagnosis; pharmaceutical preparations for use in the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of ophthalmic diseases and conditions, and for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders; pharmaceutical products for the prevention and treatment of cancer, cardiovascular diseases and genetic disorders; pharmaceutical and medical preparations and substances; drug delivery agents; drug delivery compounds that facilitate the delivery of pharmaceutical products; drug delivery agents in the form of films that facilitate the delivery of pharmaceutical products; drug delivery agents in the form of tablet coatings that facilitate the delivery of pharmaceutical productsACTIVE—
010Surgical, medical, therapeutic, dental and veterinary apparatus and instruments; drug delivery devices; medical devices used to deliver drugs, drug delivery solutions and suspensions, genes, polymers and biologics to the body; diagnostic apparatus for medical purposes; dispensing devices for the prolonged release of active agents for medical uses; inhalers for medical purposes; parts, fittings and accessories for all the aforesaid goodsACTIVE—
040Production of cell lines for use in the manufacture of biopharmaceuticals; protein fabrication, production, and manufacture for others; custom manufacture of pharmaceuticals; custom manufacture of biopharmaceuticals; Nanoparticles manufacturingACTIVE—
042Scientific, medical and industrial research and development services; clinical research; laboratory research; research and development of new drugs and clinical products; analysis of materials; chemical analysis; laboratory services; laboratory testing services; medical laboratory services; information and advisory services relating to the foregoing, including such services provided on-line from a computer network or the internet; research and development services for pharmaceuticals and for the treatment of diseases and injuries; genetic engineering services; genetic research; scientific and technological services and research and development relating thereto; genetic testing for scientific research purposes; medical and pharmacological research services; research and development in the fields of biotechnology, biopharmaceuticals and gene therapy; clinical trials; research and development of pharmaceutical preparations; development of technological platforms services for nanoparticles manufacturingACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 4, 2025FINTFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 19, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 19, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 18, 2024MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 18, 2024MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 18, 2024ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jan 12, 2024DOCKASSIGNED TO EXAMINER—
Sep 26, 2023RFNTREFUSAL PROCESSED BY IB—
Sep 4, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 4, 2023RFRRREFUSAL PROCESSED BY MPU—
Aug 15, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 14, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 8, 2023DOCKASSIGNED TO EXAMINER—
Feb 28, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 24, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 23, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance